A deeper look at the genomics of multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the need to better understand the genomics of multiple myeloma, and the benefit of observing disease progression from early stage monoclonal gammopathy of undetermined significance (MGUS) to symptomatic multiple myeloma. Dr Mohty also mentions the growing field of measurable residual disease (MRD) in myeloma, and that these fascinating topics will all be covered at this year’s COMy congress in Paris, France.